PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007000582) HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/000582 International Application No.: PCT/GB2006/002344
Publication Date: 04.01.2007 International Filing Date: 27.06.2006
Chapter 2 Demand Filed: 02.02.2007
IPC:
C07D 413/12 (2006.01) ,C07D 417/12 (2006.01) ,C07D 403/12 (2006.01) ,A61K 31/506 (2006.01) ,A61P 5/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5
Drugs for disorders of the endocrine system
02
of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Applicants:
TAKEDA CAMBRIDGE LIMITED [GB/GB]; 418 Cambridge Science Park Milton Road Cambridge CB4 0PA, GB (AllExceptUS)
SHOWELL, Graham, Andrew [GB/GB]; GB (UsOnly)
MILLER, David, John [GB/GB]; GB (UsOnly)
GLEN, Angela [GB/GB]; GB (UsOnly)
CUBILLO DE DIOS, Maria, Angeles [ES/GB]; GB (UsOnly)
MERCHANT, Kevin [GB/GB]; GB (UsOnly)
MANDAL, Ajay, Kumar [IN/GB]; GB (UsOnly)
Inventors:
SHOWELL, Graham, Andrew; GB
MILLER, David, John; GB
GLEN, Angela; GB
CUBILLO DE DIOS, Maria, Angeles; GB
MERCHANT, Kevin; GB
MANDAL, Ajay, Kumar; GB
Agent:
GILL JENNINGS & EVERY LLP; Broadgate House 7 Eldon Street London EC2M 7LH, GB
Priority Data:
0513176.828.06.2005GB
0521278.219.10.2005GB
0608846.204.05.2006GB
Title (EN) HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS
(FR) ANTAGONISTES NON-PEPTIDES HETEROCYCLIQUES DE GNRH
Abstract:
(EN) A compound of formula (I): wherein either B is absent and A and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy, -CN, -C(Rc)2OH, -N(Rd)C(=X)Rc, -C(=X)N(Rc)(Rd), -S(O)m-Rc, -N(Rc)(Rd)S(O)2, -S(O)2N(Rc)(Rd), -N(Re)2, aryl optionally substituted with Ra or -O-aryl optionally substituted with Ra; or B is present and is -(CH2)n-, -C(Rb)2- or -O-, or B taken together with A or Z can be -C=C(Rb)-, -C(Rb)=C-, -CH2-CH(Rb)- or -CH(Rb)-CH2-; D is -O- or -S(O)m,-; E is a bond or is -(CH2)n-, -N(Rd)-, -(CH2)nN(Rd)- or -N(Rd)(CH2)n-; F is -C(=X)-; G is -(CH2)n-, -N(Rd)-, -(CH2)nN(Rd)- or -N(Rd)(CH2)n; J is a bond, -O-, -N(RC)C(=X)-, -C(=X)N(Rc)-, -S(O)m,-, -N(Rc)S(O)m-, -S(O)nN(Rc)-, -N(Re)- or -N(Rg)(Rh); K is a bond, alkylene, cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene; and L is hydrogen or a terminal group; has therapeutic utility.
(FR) Composé de formule (I) possédant une utilité thérapeutique. Dans ladite formule soit B est absent et A et Z sont identiques ou différents et représentent chacun hydrogène, halogène, alkyle, hydroxy, alcoxy, -CN, -C(Rc)2OH, -N(Rd)C(=X)Rc, -C(=X)N(Rc)(Rd), -S(O)m-Rc, -N(Rc)(Rd)S(O)2, -S(O)2N(Rc)(Rd), -N(Re)2, aryle éventuellement substitué par Ra ou -O-aryle éventuellement substitué par Ra; soit B est présent et représente -(CH2)n-, -C(Rb)2- ou -O-, soit B conjointement avec A ou Z peut être représenté par -C=C(Rb)-, -C(Rb)=C-, -CH2-CH(Rb)- ou-CH(Rb)-CH2-; D représente -O- ou -S(O)m,-; E représente une liaison ou -(CH2)n-, -N(Rd)-, -(CH2)nN(Rd)- ou -N(Rd)(CH2)n-; F représente -C(=X)-; G représente -(CH2)n-, -N(Rd)-, -(CH2)nN(Rd)- ou -N(Rd)(CH2)n; J représente une liaison, -O-, -N(RC)C(=X)-, -C(=X)N(Rc)-, -S(O)m,-, -N(Rc)S(O)m-, -S(O)nN(Rc)-, -N(Re)- ou -N(Rg)(Rh); K représente une liaison, alkylène, cycloalkylène, cycloalcénylène, arylène, hétérocycloalkylène, hétérocycloalkylène ou hétéroarylène; et L représente hydrogène ou un groupe terminal.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1896465JP2008543965US20090209522CA2613162